Skip to main content
Top
Published in: Journal of Thrombosis and Thrombolysis 3/2021

01-10-2021 | Care

CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients

Authors: Ramazan Gunduz, Bekir Serhat Yildiz, Ibrahim Halil Ozdemir, Nurullah Cetin, Mehmet Burak Ozen, Eren Ozan Bakir, Su Ozgur, Ozgur Bayturan

Published in: Journal of Thrombosis and Thrombolysis | Issue 3/2021

Login to get access

Abstract

In this study, we investigated whether the CHA2DS2-VASc score could be used to estimate the need for hospitalization in the intensive care unit (ICU), the length of stay in the ICU, and mortality in patients with COVID-19. Patients admitted to Merkezefendi State Hospital because of COVID-19 diagnosis confirmed by RNA detection of virus by using polymerase chain reaction between March 24, 2020 and July 6, 2020, were screened retrospectively. The CHA2DS2-VASc and modified CHA2DS2-VASc score of all patients was calculated. Also, we received all patients’ complete biochemical markers including D-dimer, Troponin I, and c-reactive protein on admission. We enrolled 1000 patients; 791 were admitted to the general medical service and 209 to the ICU; 82 of these 209 patients died. The ROC curves of the CHA2DS2-VASc and M-CHA2DS2-VASc scores were analyzed. The cut-off values of these scores for predicting mortality were ≥ 3 (2 or under and 3). The CHA2DS2-VASc and M-CHA2DS2-VASc scores had an area under the curve value of 0.89 on the ROC. The sensitivity and specificity of the CHA2DS2-VASc scores were 81.7% and 83.8%, respectively; the sensitivity and specificity of the M-CHA2DS2-VASc scores were 85.3% and 84.1%, respectively. Multivariate logistic regression analysis showed that CHA2DS2-VASc, Troponin I, D-Dimer, and CRP were independent predictors of mortality in COVID-19 patients. Using a simple and easily available scoring system, CHA2DS2-VASc and M-CHA2DS2-VASc scores can be assessed in patients diagnosed with COVID-19. These scores can predict mortality and the need for ICU hospitalization in these patients.
Literature
1.
go back to reference Organization WH (2020) WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020. Organization WH (2020) WHO Director-General's opening remarks at the media briefing on COVID-19-11 March 2020.
2.
go back to reference Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler DJC (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281-292.e286CrossRef Walls AC, Park Y-J, Tortorici MA, Wall A, McGuire AT, Veesler DJC (2020) Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein. Cell 181(2):281-292.e286CrossRef
3.
go back to reference Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am College Cardiol 75(23):2950–2973CrossRef Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Der Nigoghossian C, Ageno W, Madjid M, Guo Y et al (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up: JACC state-of-the-art review. J Am College Cardiol 75(23):2950–2973CrossRef
4.
go back to reference Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, Kaptein F, van Paassen J, Stals M, Huisman M (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147CrossRef Klok F, Kruip M, Van der Meer N, Arbous M, Gommers D, Kant K, Kaptein F, van Paassen J, Stals M, Huisman M (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res 191:145–147CrossRef
5.
go back to reference Guan W-J, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui D (2020) Clinical characteristics of coronavirus disease 2019 in China. New England J Med 382(18):1708–1720CrossRef Guan W-J, Ni Z-y, Hu Y, Liang W-h, Ou C-q, He J-x, Liu L, Shan H, Lei C-l, Hui D (2020) Clinical characteristics of coronavirus disease 2019 in China. New England J Med 382(18):1708–1720CrossRef
6.
go back to reference Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef Tang N, Li D, Wang X, Sun Z (2020) Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 18(4):844–847CrossRef
7.
go back to reference Yatskar L, Harari R, Shah B (2020) ST-segment elevation in patients with covid-19: a case series. N Engl J Med 17(382):2478–2480 Yatskar L, Harari R, Shah B (2020) ST-segment elevation in patients with covid-19: a case series. N Engl J Med 17(382):2478–2480
8.
go back to reference Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M (2020) Neurologic features in severe SARS-CoV-2 infection. New England J Med 382(323):2268–2270CrossRef Helms J, Kremer S, Merdji H, Clere-Jehl R, Schenck M, Kummerlen C, Collange O, Boulay C, Fafi-Kremer S, Ohana M (2020) Neurologic features in severe SARS-CoV-2 infection. New England J Med 382(323):2268–2270CrossRef
9.
go back to reference Helms J, Tacquard C, Severac FJICM (2020) (Clinical research in intensive care and sepsis trial group for global evaluation and research in sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 4:1–10 Helms J, Tacquard C, Severac FJICM (2020) (Clinical research in intensive care and sepsis trial group for global evaluation and research in sepsis). High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. Intensive Care Med 4:1–10
10.
go back to reference Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger K (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. New England J Med 382(20):e60CrossRef Oxley TJ, Mocco J, Majidi S, Kellner CP, Shoirah H, Singh IP, De Leacy RA, Shigematsu T, Ladner TR, Yaeger K (2020) Large-vessel stroke as a presenting feature of Covid-19 in the young. New England J Med 382(20):e60CrossRef
11.
go back to reference Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie AJTL (2020) Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet 395(10236):1546CrossRef Perini P, Nabulsi B, Massoni CB, Azzarone M, Freyrie AJTL (2020) Acute limb ischaemia in two young, non-atherosclerotic patients with COVID-19. Lancet 395(10236):1546CrossRef
12.
go back to reference Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5(7):802–810CrossRef Shi S, Qin M, Shen B, Cai Y, Liu T, Yang F, Gong W, Liu X, Liang J, Zhao Q (2020) Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol 5(7):802–810CrossRef
13.
go back to reference Cetinkal G, Kocas BB, Ser OS, Kilci H, Keskin K, Ozcan SN, Verdi Y, Zeren MI, Demir T, Kilickesmez K (2020) Assessment of the modified CHA2DS2VASc risk score in predicting mortality in patients hospitalized with COVID-19. Am J Cardiol 135:143–149CrossRef Cetinkal G, Kocas BB, Ser OS, Kilci H, Keskin K, Ozcan SN, Verdi Y, Zeren MI, Demir T, Kilickesmez K (2020) Assessment of the modified CHA2DS2VASc risk score in predicting mortality in patients hospitalized with COVID-19. Am J Cardiol 135:143–149CrossRef
14.
go back to reference Organization WH (2020) Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization Organization WH (2020) Laboratory testing for coronavirus disease 2019 (COVID-19) in suspected human cases: interim guidance, 2 March 2020. World Health Organization
15.
go back to reference Shoker A, Hossain M, Sengul T, Raju D, Cockcroft D (2006) Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 66(2):89–97CrossRef Shoker A, Hossain M, Sengul T, Raju D, Cockcroft D (2006) Performance of creatinine clearance equations on the original Cockcroft-Gault population. Clin Nephrol 66(2):89–97CrossRef
16.
go back to reference Kurtul A, Acikgoz S (2017) Validation of the CHA2DS2-VASc score in predicting coronary atherosclerotic burden and in-hospital mortality in patients with acute coronary syndrome. Am J Cardiol 120(1):8–14CrossRef Kurtul A, Acikgoz S (2017) Validation of the CHA2DS2-VASc score in predicting coronary atherosclerotic burden and in-hospital mortality in patients with acute coronary syndrome. Am J Cardiol 120(1):8–14CrossRef
17.
go back to reference Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062CrossRef Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, Xiang J, Wang Y, Song B, Gu X (2020) Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395(10229):1054–1062CrossRef
18.
go back to reference Xu J-b, Xu C, Zhang R-b, Wu M, Pan C-k, Li X-j, Wang Q, Zeng F-f, Zhu S (2020) Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep 10(1):1–10CrossRef Xu J-b, Xu C, Zhang R-b, Wu M, Pan C-k, Li X-j, Wang Q, Zeng F-f, Zhu S (2020) Associations of procalcitonin, C-reaction protein and neutrophil-to-lymphocyte ratio with mortality in hospitalized COVID-19 patients in China. Sci Rep 10(1):1–10CrossRef
19.
go back to reference Liu S, Yao N, Qiu Y, He C et al (2020) Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease. Am J Emerg Med 38(10):2074–2080CrossRef Liu S, Yao N, Qiu Y, He C et al (2020) Predictive performance of SOFA and qSOFA for in-hospital mortality in severe novel coronavirus disease. Am J Emerg Med 38(10):2074–2080CrossRef
20.
go back to reference Zhang L, Yan X, Fan Q, Liu H, Liu X, LiuZhang ZZ et al (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18(6):1324–1329CrossRef Zhang L, Yan X, Fan Q, Liu H, Liu X, LiuZhang ZZ et al (2020) D-dimer levels on admission to predict in-hospital mortality in patients with Covid-19. J Thromb Haemost 18(6):1324–1329CrossRef
21.
go back to reference Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch HJTL (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418CrossRef Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch HJTL (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418CrossRef
22.
go back to reference Levi M, Thachil J, Iba T, Levy JHJTLH (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7(6):e438CrossRef Levi M, Thachil J, Iba T, Levy JHJTLH (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7(6):e438CrossRef
23.
go back to reference Çınar T, Hayıroğlu MI, Tanık VO, Aruğaslan E, Keskin M, Uluganyan M, Öz A, Çağdaş M, Alper AT et al (2018) The predictive value of the CHA2DS2-VASc score in patients with mechanical mitral valve thrombosis. J Thromb Thromb 45(4):571–577CrossRef Çınar T, Hayıroğlu MI, Tanık VO, Aruğaslan E, Keskin M, Uluganyan M, Öz A, Çağdaş M, Alper AT et al (2018) The predictive value of the CHA2DS2-VASc score in patients with mechanical mitral valve thrombosis. J Thromb Thromb 45(4):571–577CrossRef
24.
go back to reference Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA et al (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score. BMJ 370:m3339CrossRef Knight SR, Ho A, Pius R, Buchan I, Carson G, Drake TM, Dunning J, Fairfield CJ, Gamble C, Green CA et al (2020) Risk stratification of patients admitted to hospital with covid-19 using the ISARIC WHO clinical characterisation protocol: development and validation of the 4C Mortality Score. BMJ 370:m3339CrossRef
25.
go back to reference Yadaw AS, Li Y-C, Bose S, Iyengar R, Bunyavanich S, Pandey GJTLDH (2020) Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health 2(10):e516–e525CrossRef Yadaw AS, Li Y-C, Bose S, Iyengar R, Bunyavanich S, Pandey GJTLDH (2020) Clinical features of COVID-19 mortality: development and validation of a clinical prediction model. Lancet Digit Health 2(10):e516–e525CrossRef
Metadata
Title
CHA2DS2-VASc score and modified CHA2DS2-VASc score can predict mortality and intensive care unit hospitalization in COVID-19 patients
Authors
Ramazan Gunduz
Bekir Serhat Yildiz
Ibrahim Halil Ozdemir
Nurullah Cetin
Mehmet Burak Ozen
Eren Ozan Bakir
Su Ozgur
Ozgur Bayturan
Publication date
01-10-2021
Publisher
Springer US
Keywords
Care
COVID-19
Published in
Journal of Thrombosis and Thrombolysis / Issue 3/2021
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-021-02427-1

Other articles of this Issue 3/2021

Journal of Thrombosis and Thrombolysis 3/2021 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.